Published in Gastroenterology on May 01, 2007
Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell (2010) 8.04
NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res (2010) 4.10
Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology (2008) 2.70
Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell (2010) 2.43
Deletion of Fas in adipocytes relieves adipose tissue inflammation and hepatic manifestations of obesity in mice. J Clin Invest (2009) 2.39
c-Jun N-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice. Gastroenterology (2009) 1.59
Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis. J Hepatol (2010) 1.56
Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice. Sci Signal (2012) 1.50
Tlr2 is critical for diet-induced metabolic syndrome in a murine model. FASEB J (2009) 1.40
Resveratrol inhibits nonalcoholic fatty liver disease in rats. BMC Gastroenterol (2008) 1.37
Role of scavenger receptor A and CD36 in diet-induced nonalcoholic steatohepatitis in hyperlipidemic mice. Gastroenterology (2010) 1.33
Redox mechanisms in hepatic chronic wound healing and fibrogenesis. Fibrogenesis Tissue Repair (2008) 1.30
Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease. J Proteome Res (2010) 1.29
Template to improve glycemic control without reducing adiposity or dietary fat. Am J Physiol Endocrinol Metab (2011) 1.25
Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS One (2009) 1.25
Inflammatory cause of metabolic syndrome via brain stress and NF-κB. Aging (Albany NY) (2012) 1.24
Death receptor 5 signaling promotes hepatocyte lipoapoptosis. J Biol Chem (2011) 1.23
Metabolic syndrome, aging and involvement of oxidative stress. Aging Dis (2015) 1.22
Internalization of modified lipids by CD36 and SR-A leads to hepatic inflammation and lysosomal cholesterol storage in Kupffer cells. PLoS One (2012) 1.16
Glycogen synthase kinase-3 (GSK-3) inhibition attenuates hepatocyte lipoapoptosis. J Hepatol (2010) 1.13
Specific immunization strategies against oxidized low-density lipoprotein: a novel way to reduce nonalcoholic steatohepatitis in mice. Hepatology (2012) 1.13
PPAR/RXR Regulation of Fatty Acid Metabolism and Fatty Acid omega-Hydroxylase (CYP4) Isozymes: Implications for Prevention of Lipotoxicity in Fatty Liver Disease. PPAR Res (2010) 1.11
Hypothalamic inflammation: a double-edged sword to nutritional diseases. Ann N Y Acad Sci (2011) 1.11
Mcl-1 degradation during hepatocyte lipoapoptosis. J Biol Chem (2009) 1.09
The use of sibutramine in the management of obesity and related disorders: an update. Vasc Health Risk Manag (2009) 1.09
Coactivation of AKT and β-catenin in mice rapidly induces formation of lipogenic liver tumors. Cancer Res (2011) 1.09
Mechanisms and clinical implications of hepatocyte lipoapoptosis. Clin Lipidol (2010) 1.07
Ginsenoside Rb1 reduces fatty liver by activating AMP-activated protein kinase in obese rats. J Lipid Res (2013) 1.01
Regulation of glucose and lipid homeostasis by adiponectin: effects on hepatocytes, pancreatic β cells and adipocytes. Best Pract Res Clin Endocrinol Metab (2013) 0.99
Mixed lineage kinase 3 deficient mice are protected against the high fat high carbohydrate diet-induced steatohepatitis. Liver Int (2013) 0.96
Distinct effects of calorie restriction and resveratrol on diet-induced obesity and Fatty liver formation. J Nutr Metab (2011) 0.95
The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings. Br J Pharmacol (2011) 0.94
Hepatitis B virus X protein impairs hepatic insulin signaling through degradation of IRS1 and induction of SOCS3. PLoS One (2010) 0.93
Lipoic acid improves hypertriglyceridemia by stimulating triacylglycerol clearance and downregulating liver triacylglycerol secretion. Arch Biochem Biophys (2009) 0.93
Ceramide as a mediator of non-alcoholic Fatty liver disease and associated atherosclerosis. PLoS One (2015) 0.93
Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease. World J Hepatol (2013) 0.92
Role of innate immune response in non-alcoholic Fatty liver disease: metabolic complications and therapeutic tools. Front Immunol (2014) 0.92
Differential effects of krill oil and fish oil on the hepatic transcriptome in mice. Front Genet (2011) 0.92
Aminotransferase levels are associated with cardiometabolic risk above and beyond visceral fat and insulin resistance: the Framingham Heart Study. Arterioscler Thromb Vasc Biol (2012) 0.91
Obesity, autophagy and the pathogenesis of liver and pancreatic cancers. J Gastroenterol Hepatol (2012) 0.91
Protective effect of whey proteins against nonalcoholic fatty liver in rats. Lipids Health Dis (2011) 0.90
Inhibitory effect of schisandrin B on free fatty acid-induced steatosis in L-02 cells. World J Gastroenterol (2011) 0.90
Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. Am J Clin Nutr (2012) 0.89
Metabolomic changes in fatty liver can be modified by dietary protein and calcium during energy restriction. World J Gastroenterol (2008) 0.88
Metabolic and tissue-specific regulation of acyl-CoA metabolism. PLoS One (2015) 0.88
Lipotoxic effect of p21 on free fatty acid-induced steatosis in L02 cells. PLoS One (2014) 0.86
Clinicopathological characteristics and metabolic profiles of non-alcoholic fatty liver disease in Indian patients with normal body mass index: Do they differ from obese or overweight non-alcoholic fatty liver disease? Indian J Endocrinol Metab (2013) 0.86
The role of redox mechanisms in hepatic chronic wound healing and fibrogenesis. Fibrogenesis Tissue Repair (2012) 0.84
Hypertension and other morbidities with Cushing's syndrome associated with corticosteroids: a review. Integr Blood Press Control (2011) 0.84
Dietary d-limonene alleviates insulin resistance and oxidative stress-induced liver injury in high-fat diet and L-NAME-treated rats. Eur J Nutr (2011) 0.83
Chemical induction of the unfolded protein response in the liver increases glucose production and is activated during insulin-induced hypoglycaemia in rats. Diabetologia (2008) 0.83
Role of gut microbiota in liver diseases. Hepatol Res (2012) 0.82
COH-SR4 reduces body weight, improves glycemic control and prevents hepatic steatosis in high fat diet-induced obese mice. PLoS One (2013) 0.81
Ethanol extract of Cirsium japonicum attenuates hepatic lipid accumulation via AMPK activation in human HepG2 cells. Exp Ther Med (2014) 0.80
Saturated free fatty acid sodium palmitate-induced lipoapoptosis by targeting glycogen synthase kinase-3β activation in human liver cells. Dig Dis Sci (2013) 0.80
Beta-Glucan-Rich Extract from Pleurotus sajor-caju (Fr.) Singer Prevents Obesity and Oxidative Stress in C57BL/6J Mice Fed on a High-Fat Diet. Evid Based Complement Alternat Med (2013) 0.80
Deletion of nardilysin prevents the development of steatohepatitis and liver fibrotic changes. PLoS One (2014) 0.79
Non-alcoholic fatty liver disease and psoriasis: So far, so near. World J Hepatol (2015) 0.79
Hepatic angiogenesis and fibrosis are common features in morbidly obese patients. Hepatol Int (2011) 0.79
Effect of inhaled corticosteroids on glycemic status. Open Respir Med J (2014) 0.79
The role of lipid droplet formation in the protection of unsaturated fatty acids against palmitic acid induced lipotoxicity to rat insulin-producing cells. Nutr Metab (Lond) (2016) 0.78
Relationship between obesity, metabolic syndrome, and nonalcoholic fatty liver disease in the elderly agricultural and fishing population of Taiwan. Clin Interv Aging (2014) 0.78
Noninvasive markers for the diagnosis of nonalcoholic Fatty liver disease. Endocrinol Metab (Seoul) (2013) 0.77
PDIA3 Knockdown Exacerbates Free Fatty Acid-Induced Hepatocyte Steatosis and Apoptosis. PLoS One (2015) 0.77
Smad7 dependent expression signature highlights BMP2 and HK2 signaling in HSC transdifferentiation. World J Gastroenterol (2010) 0.77
Transcriptional networks implicated in human nonalcoholic fatty liver disease. Mol Genet Genomics (2015) 0.77
Kinetic assessment and therapeutic modulation of metabolic and inflammatory profiles in mice on a high-fat and cholesterol diet. PPAR Res (2010) 0.76
Bai-Hu-Jia-Ren-Shen-Tang Decoction Reduces Fatty Liver by Activating AMP-Activated Protein Kinase In Vitro and In Vivo. Evid Based Complement Alternat Med (2015) 0.76
Probiotic antigens stimulate hepatic natural killer T cells. Immunology (2014) 0.76
Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice. PLoS One (2017) 0.75
FoxO3 increases miR-34a to cause palmitate-induced cholangiocyte lipoapoptosis. J Lipid Res (2017) 0.75
Low-density lipoprotein particle size in hepatic steatosis and metabolic syndrome. Diabetol Metab Syndr (2010) 0.75
The relationship of serum alanine aminotransferase normal-range levels to arterial stiffness and metabolic syndrome in non-drinkers and drinkers: a Chinese community-based analysis. BMC Gastroenterol (2017) 0.75
The Metabolic Implications of Glucocorticoids in a High-Fat Diet Setting and the Counter-Effects of Exercise. Metabolites (2016) 0.75
Abdominal Subcutaneous Fat Thickness Measured by Ultrasonography Correlates with Hyperlipidemia and Steatohepatitis in Obese Children. Pediatr Gastroenterol Hepatol Nutr (2015) 0.75
Glycated Hemoglobin Levels in Patients with Decompensated Cirrhosis. Int J Endocrinol (2016) 0.75
Gender-differences in the associations between circulating creatine kinase, blood pressure, body mass and non-alcoholic fatty liver disease in asymptomatic asians. PLoS One (2017) 0.75
Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res (2007) 2.50
Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology (2002) 2.10
Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology (2006) 2.08
Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology (2010) 1.86
Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology (2005) 1.81
An assessment of statin safety by hepatologists. Am J Cardiol (2006) 1.78
Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor. Cancer Res (2008) 1.67
The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. Am J Pathol (2005) 1.49
leptin-induced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to CYCLIN D1 promoter via activation of Stat3. J Biol Chem (2007) 1.48
Shanthi V. Sitaraman, MD, PhD: physician, scientist, educator, and humanitarian. Gastroenterology (2011) 1.39
Racial differences in liver inflammation and fibrosis related to chronic hepatitis C. Clin Gastroenterol Hepatol (2004) 1.32
GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS One (2011) 1.26
Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology (2010) 1.23
Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma. Gastroenterology (2010) 1.20
Epstein-Barr virus induced hepatitis: An important cause of cholestasis. Hepatol Res (2005) 1.20
Leptin induces increased alpha2(I) collagen gene expression in cultured rat hepatic stellate cells. J Cell Biochem (2003) 1.19
Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. Am J Physiol Gastrointest Liver Physiol (2011) 1.19
Leptin increases tissue inhibitor of metalloproteinase I (TIMP-1) gene expression by a specificity protein 1/signal transducer and activator of transcription 3 mechanism. Mol Endocrinol (2006) 1.09
Adiponectin activation of AMPK disrupts leptin-mediated hepatic fibrosis via suppressors of cytokine signaling (SOCS-3). J Cell Biochem (2010) 1.07
Murine alanine aminotransferase: cDNA cloning, functional expression, and differential gene regulation in mouse fatty liver. Hepatology (2004) 1.06
Adiponectin inhibits leptin signalling via multiple mechanisms to exert protective effects against hepatic fibrosis. Biochem J (2011) 0.99
Antagonistic interaction between Wnt and Notch activity modulates the regenerative capacity of a zebrafish fibrotic liver model. Hepatology (2014) 0.90
The prevalence and clinical correlates of nonalcoholic fatty liver disease (NAFLD) in African Americans: the multiethnic study of atherosclerosis (MESA). Dig Dis Sci (2013) 0.88
Terbinafine hepatotoxicity resulting in chronic biliary ductopenia and portal fibrosis. Am J Med (2002) 0.87
The role of gastrointestinal hormones in hepatic lipid metabolism. Semin Liver Dis (2013) 0.83
Treatment of fibrosis in nonalcoholic fatty liver disease. Curr Gastroenterol Rep (2007) 0.78
Glial cell line-derived neurotrophic factor protects against high-fat diet-induced obesity. Am J Physiol Gastrointest Liver Physiol (2014) 0.78
Chlorzoxazone as a cause of acute liver failure requiring liver transplantation. Dig Dis Sci (2007) 0.77
Adiponectin and alcoholic fatty liver: Is it, after all, about what you eat? Hepatology (2005) 0.77
Connecting the dots from fatty acids to nonalcoholic steatohepatitis: epigenetics in the spotlight. Hepatology (2013) 0.75
The Diabetes Prevention Program and the metabolic syndrome. Ann Intern Med (2005) 0.75
Increased liver enzyme levels and HNF-1beta gene mutation. Clin Gastroenterol Hepatol (2008) 0.75
Recent changes in relationships between medical school physicians and industry. Gastroenterology (2010) 0.75
Hepatorenal syndrome. Definition, pathophysiology, and intervention. Crit Care Clin (2002) 0.75